Single User License
INR 129920
Site License
INR 259840
Corporate User License
INR 389760

Service Tax Additional

select a format

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Lipodystrophy-Pipeline Review, H1 2015

Lipodystrophy-Pipeline Review, H1 2015

  • Products Id :- GMDHC6326IDB
  • |
  • Pages: 53
  • |
  • February 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Lipodystrophy-Pipeline Review, H1 2015


Global Markets Direct's, 'Lipodystrophy-Pipeline Review, H1 2015', provides an overview of the Lipodystrophy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lipodystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lipodystrophy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Lipodystrophy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Lipodystrophy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Lipodystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Lipodystrophy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Lipodystrophy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Lipodystrophy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Lipodystrophy Overview 6

Therapeutics Development 7

Pipeline Products for Lipodystrophy-Overview 7

Pipeline Products for Lipodystrophy-Comparative Analysis 8

Lipodystrophy-Therapeutics under Development by Companies 9

Lipodystrophy-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Lipodystrophy-Products under Development by Companies 13

Lipodystrophy-Companies Involved in Therapeutics Development 14

Aileron Therapeutics, Inc. 14

Ambrx, Inc. 15

AstraZeneca PLC 16

Bolder Biotechnology, Inc. 17

Theratechnologies Inc. 18

Zydus Cadila Healthcare Limited 19

Lipodystrophy-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

ALRN-5281-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

ARX-328-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

BBT-031-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

metreleptin-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

saroglitazar-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

tesamorelin acetate-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Lipodystrophy-Recent Pipeline Updates 39

Lipodystrophy-Dormant Projects 45

Lipodystrophy-Product Development Milestones 46

Featured News & Press Releases 46

May 29, 2014: Zydus Explores Newer Treatment Options With its Breakthrough Drug, Lipaglyn 46

May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States 46

May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States 47

Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease 47

Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin 48

Sep 18, 2013: EMD Serono Notifies FDA of a Shortage of Tesamorelin 49

Jul 08, 2013: Theratechnologies Inc./Request for Reconsideration in Canada: Meeting With Scientific Advisory Committee Authorized 49

Jun 28, 2013: Theratechnologies Provides Regulatory Update for Colombia 49

Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin 50

May 07, 2013: Aileron Therapeutics Successfully Completes Stapled Peptide Clinical Trial 50

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

Number of Products under Development for Lipodystrophy, H1 2015 7

Number of Products under Development for Lipodystrophy-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Development, H1 2015 12

Products under Development by Companies, H1 2015 13

Lipodystrophy-Pipeline by Aileron Therapeutics, Inc., H1 2015 14

Lipodystrophy-Pipeline by Ambrx, Inc., H1 2015 15

Lipodystrophy-Pipeline by AstraZeneca PLC, H1 2015 16

Lipodystrophy-Pipeline by Bolder Biotechnology, Inc., H1 2015 17

Lipodystrophy-Pipeline by Theratechnologies Inc., H1 2015 18

Lipodystrophy-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 19

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Stage and Target, H1 2015 22

Number of Products by Stage and Mechanism of Action, H1 2015 24

Number of Products by Stage and Route of Administration, H1 2015 26

Number of Products by Stage and Molecule Type, H1 2015 28

Lipodystrophy Therapeutics-Recent Pipeline Updates, H1 2015 39

Lipodystrophy-Dormant Projects, H1 2015 45

List of Figures

Number of Products under Development for Lipodystrophy, H1 2015 7

Number of Products under Development for Lipodystrophy-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Top 10 Targets, H1 2015 21

Number of Products by Stage and Top 10 Targets, H1 2015 22

Number of Products by Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24

Number of Products by Top 10 Routes of Administration, H1 2015 25

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 26

Number of Products by Top 10 Molecule Types, H1 2015 27

Number of Products by Stage and Top 10 Molecule Types, H1 2015 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Aileron Therapeutics, Inc.

Ambrx, Inc.

AstraZeneca PLC

Bolder Biotechnology, Inc.

Theratechnologies Inc.

Zydus Cadila Healthcare Limited

Lipodystrophy Therapeutic Products under Development, Key Players in Lipodystrophy Therapeutics, Lipodystrophy Pipeline Overview, Lipodystrophy Pipeline, Lipodystrophy Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]